Dorothea Heldt, MSc, is a Research Analyst in the Strategic Market Access Centre of Excellence based in Pharmerit’s Berlin office. Her expertise includes systematic literature reviews and Digital Therapeutics.
Prior to joining Pharmerit, Dorothea was involved in researching autophagy regulation in Pulmonary Arterial Hypertension at the LUMC in the Netherlands. During her studies, she joined Pharmerit to investigate approval procedures and criteria of Digital Therapeutics in Europe and in the US. In addition, she supported the Business Development team. She holds a Bachelor’s degree in Biology from Freie Universität Berlin and a Master’s degree in Biology and Business Studies from Leiden University.